| Name | Title | Contact Details |
|---|
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
Compass Health Northwest Washington’s Behavioral Healthcare Leader Access Services Compass Health provides comprehensive services to treat behavioral health…
J M Smith Corporation is a Spartanburg, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharmacy OneSource is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headcan is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.